Heidelberg Pharma AG confirmed its full-year financial guidance issued on 19 March 2020. The Executive Management Board expects the Group to generate between EUR 8.0 million and EUR 10.0 million in sales revenue and other income (2019: EUR 8.0 million) for the 2020 fiscal year. This planning takes into account additional potential cash inflows from new licensing activities. Based on current planning, operating expenses are expected to be in the range of EUR 20.0 million to EUR 24.0 million, higher than in 2019 (EUR 18.1 million). Loss before interest and taxes (EBIT) for 2020 are expected to be between EUR 11.0 million and EUR 15.0 million (2019: EUR 10.1 million).